NL-OMON31546
Completed
Not Applicable
A Phase 1 Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of the Selective Met Inhibitor, JNJ 38877605 in Subjects With Advanced or Refractory Solid Tumors. - N/A
Johnson & Johnson Pharmaceutical0 sites33 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Advanced or Refractory Solid Tumors
- Sponsor
- Johnson & Johnson Pharmaceutical
- Enrollment
- 33
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •histologically or cytologically confirmed advanced or refractory solid
- •tumor and no longer eligible for approved, available standard therapies
Exclusion Criteria
- •known brain metastases
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid TumoursNL-OMON51802DeuterOncology NV15
Recruiting
Not Applicable
A Phase 1 trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies.relapsed or refractory lymphoid malignancy, relapsed/refractory multiple myeloma, relapsed/refractory Hodgkins lymphoma, relapsed/refractory peripheral T-cell lymphoma, relapsed/refractory cutaneous T-cell lymphoma, subtypes mycosis fungoides and Sézary syndrome, relapsed/refractory T-cell Prolymphocytic leukemia. Note: Recruitment to the CTCL and T-PLL cohorts was halted on 01 March 2021.Relapsed/ refractory Hematologic Malignancies10025319NL-OMON52700Mundipharma Research Limited10
Not yet recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod in Subjects with Chronic Hepatitis B InfectioChronic Hepatitis B InfectionInfection - Other infectious diseasesACTRN12624000808549Bluejay Therapeutics, Inc40
Not yet recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod in Subjects with Chronic Hepatitis B InfectioChronic Hepatitis B InfectionInfection - Other infectious diseasesACTRN12624000809538Bluejay Therapeutics, Inc80
Unknown
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients with Advanced or Refractory Solid Tumors or LymphomaJPRN-jRCT2080223021Janssen Pharmaceutical K.K.33